European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Sparingvision SAS, Paris, France

Watch
Sparingvision SAS

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier provides comprehensive company details as a PDF, together with all underlying original publications and original data in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Power Dossier
Entire company details along with all original publications / original data bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more
Learn more
View plans

Name

Sparingvision SAS
Sparing Vision SAS
Spare Vision SAS

Identification

Sirul
Siren 821148327
Lei
969500V4TM7NAYAGXV60
Siret
Siret 82114832700041
EUID
FR7501.821148327

Address

5 Percier, 75008 Paris, France

Corporate purpose

72.19
Other research and experimental development on natural sciences and engineering

Research and development of innovative therapies in the field of retinal degeneration.

Financial performance

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Network

Loading network

Legal Structure

Current legal representatives Legal form information Premium
Premium
2President
1Deputy CEO
3Member of the Executive Board
2Member of the Supervisory Board
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Total assets
Earnings
Revenue
Revenue CAGR
Return on sales
Equity
Equity ratio
Return on equity
Employee number
Revenue per employee
Cash on hand
Receivables
Liabilities
Patents
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans
Financial Statements Interactive sheets with CSV/Excel download Premium
Premium
Balance
from 2017 to 2025
Profit & Loss
from 2017 to 2018
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

20 Sept 2026
Capital: €1,599,828
18 Aug 2026
Capital: €1,599,999
18 Aug 2026
Capital: €1,599,054
28 Jun 2026 also 17/07/2025, 29/08/2024, 25/08/2023, 13/07/2022, 18/06/2021, 22/12/2020, 19/07/2019, 02/08/2018, 17/11/2017
Bulletin officiel des annonces civiles et commerciales
11 Jun 2026
Annual report for the year ending 31/12/2025 · Balance sheet for 31/12/2025
5 Jun 2026
Capital: €1,599,998
4 Mar 2026
Capital: €1,599,997
20 Jan 2026
Capital: €1,579,059
20 Jan 2026
Capital: €1,537,921
20 Jan 2026
Capital: €1,597,856
17 Dec 2025
Capital: €1,578,094
13 Nov 2025
Capital: €1,578,084
6 Aug 2025
Capital: €1,577,646
6 Jul 2025
Capital: €1,463,363
6 Jun 2025
Capital: €1,174,679
2 Apr 2025
Patent: Compositions and procedures for the treatment of degenerative retinal diseases
22 Jan 2025
Capital: €1,174,027
17 Jul 2024
Capital: €1,180,708
23 Apr 2024
Capital: €1,180,705
17 Apr 2024
Capital: €1,180,050
27 Mar 2024
Capital: €1,180,029
7 Feb 2024
President: Stéphane Boissel · Capital: €1,178,729
20 Oct 2023
Patent: G-Protein-Gated-K+ Channel-Mediated Enhancements in Light Sensitivity in ROD-Cone Dystrophy (RCD)
20 Oct 2023
Patent: Compositions and procedures for the treatment of degenerative retinal diseases
20 Jul 2023
Capital: €1,178,729
2 Jun 2023
Member of the Executive Board: Joseph Papa · No longer Deputy CEO: Joseph Papa · Capital: €845,409
31 May 2023
Patent: Constructs Comprising Neuronal Viability Factors and Uses Thereof
30 May 2023
Member of the Executive Board: Joseph C. Papa · Deputy CEO: Joseph C. Papa
24 May 2023
President: Joseph C. Papa
7 May 2023
Member of the Executive Board: Joseph Papa · No longer Deputy CEO: Stéphane Boissel · Capital: €845,409
27 Apr 2023
Member of the Supervisory Board: Joseph C. Papa · No longer Chair of the Supervisory Board: Stéphane Boissel
19 Oct 2022
Capital: €844,334
11 Oct 2022
No longer Member of the Executive Board: Geoffroy Frevol
11 Oct 2022
Patent: G-Protein-Gated-K+ Channel-Mediated Enhancements in Light Sensitivity in Patients with ROD-Cone Dystrophy (RCD)
2 Aug 2022
Member of the Supervisory Board: Stéphane Boissel
28 Jul 2022
President: Stéphane Boissel
17 Jul 2022
No longer Auditor (2 companies) · Capital: €777,670
25 May 2022
Patent: G-Protein-Gated-K+ Channel-Mediated Enhancements in Light Sensitivity in ROD-Cone Dystrophy (RCD)
4 May 2022
Capital: €777,670
5 Apr 2022
Reg­is­tra­tion: 05/04/2022 · Address · Legal form: SAS, société par actions simplifiée · Name: SPARINGVISION · Segment clas­si­fi­ca­tion
23 Feb 2022
Capital: €777,220
25 Nov 2021
Capital: €757,154
21 Oct 2021
Member of the Executive Board: Geoffroy Frevol · Capital: €451,338
17 Oct 2021
Capital: €451,338
13 Oct 2021
Member of the Supervisory Board: Geoffroy Frevol · Member of the Supervisory Board: Foundation Fighting Blindness Retinal Degeneration Fund Société de droit étranger
12 Oct 2021
Member of the Supervisory Board: Geoffroy Frevol
4 Jul 2021
Capital: €444,650
20 Jun 2021
Auditor: Ernst & Young Audit · Capital: €383,926
10 Jun 2021
Auditor: Ernst & Young Audit SAS
13 Apr 2021
Capital: €383,926
18 Feb 2021
Capital: €383,926 · Corporate Purpose
21 Jan 2021
President: Stéphane Boissel · Member of the Supervisory Board: Stéphane Boissel · Member of the Supervisory Board: Foundation Fighting Blindness Retinal Degeneration Fund Société de droit étranger
17 Jan 2021
Capital: €383,926
4 Jan 2021
Address
30 Dec 2020
Member of the Executive Board: Ysios Capital Partners Sgeic · Capital: €382,701
30 Dec 2020
Capital: €335,201
24 Dec 2020
Member of the Executive Board: Jeanne M. Cunicelli, Owen Smith · No longer CxO (5) · CxO: Foundation Fighting Blindness Retinal Degeneration Fund, Jeito SLP · Capital: €285,201
15 Dec 2020
Member of the Supervisory Board: Jeanne M. Cunicelli, Owen Smith · No longer Member of the Supervisory Board (5) · SB: Foundation Fighting Blindness Retinal Degeneration Fund, Jeito SLP
12 Nov 2020
President: Stéphane Boissel · No longer President (1) · Capital: €161,426
19 Apr 2020
Member of the Executive Board: Stéphane Boissel · Deputy CEO: Stéphane Boissel · Capital: €161,426
9 Apr 2020
President: Stéphane Boissel · Member of the Supervisory Board: Stéphane Boissel · Auditor: Beas SAS, Deloitte & Associés SA
31 Jan 2020
Capital: €161,426
1 Aug 2019 in Hor
EU funding (€2,470,715): Sparing gene therapy for Inherited ROd COne dystrophies
3 Jul 2019
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018 · Earnings statement for 31/12/2018
6 Mar 2019
President (1)
7 Feb 2019
President (1)
15 Mar 2018
Capital: €100,000
13 Mar 2018
Member of the Executive Board: Benjamin Yerxa · No longer Member of the Executive Board: Patricia Zilliox · Capital: €40,000
2 Mar 2018
Member of the Supervisory Board: Benjamin Yerxa · No longer Member of the Supervisory Board: Patricia Zilliox
1 Feb 2018
Address
19 Mar 2017
Capital: €40,000 · Corporate Purpose
8 Mar 2017
Member of the Supervisory Board (5) · President (1) · Member of the Supervisory Board: Bpifrance Investissement SAS · Auditor: Beas SAS, Deloitte & Associés SA
15 Feb 2017
Address
4 Jan 2017
Capital: €40,000
3 Jan 2017 as Sparing Vision SAS
Member of the Executive Board (5) · Member of the Executive Board: Bpifrance Investissement · Capital: €40,000
6 Sept 2016 as Sparing Vision SAS
No longer President: Jean-Charles Pomerol · President (1) · Capital: €20,000
1 Aug 2016
Name: SPARINGVISION
24 Jul 2016 as Sparing Vision SAS
Capital: €20,000
8 Jul 2016 as Sparing Vision SAS
Name: SPARING VISION
5 Jul 2016 as Spare Vision SAS
Reg­is­tra­tion: 23/06/2016 · President: Jean-Charles Pomerol · Auditor: Beas, Deloitte & Associés · Capital: €20,000 · Corporate Purpose
22 Jun 2016 as Spare Vision SAS
Address · Legal form: SAS, société par actions simplifiée · Name: SPARE VISION · Segment clas­si­fi­ca­tion
There are no publications matching your search.

Mentions

6 Oct 2026 in Rne
Sparingvision Inc
25 Sept 2026 in Rne
Reg­is­tra­tion: 22/06/2016 · President: Stephane Boissel · Auditor: Ernst & Young Audit SAS · Capital: €1,599,828 · Segment clas­si­fi­ca­tion · Corporate Purpose
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.